Investigation of the Influence of the Human Microbiome on Giant Cell Arteritis
Launched by UNIVERSITY OF BONN · Feb 22, 2024
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how the human microbiome, especially the bacteria in our gut, may affect the development and progression of Giant Cell Arteritis (GCA), a condition that causes inflammation in the blood vessels. Researchers will compare the microbiomes of people diagnosed with GCA to those of healthy individuals at the time of diagnosis and again after six months. By doing this, they hope to identify specific bacteria that may influence the immune system and contribute to GCA.
To participate in this trial, individuals must be diagnosed with Giant Cell Arteritis and be between the ages of 65 and 74. However, certain health conditions, like chronic infections or gastrointestinal diseases, may exclude someone from participating. If eligible, participants will provide samples of their oral, blood, and gut microbiomes, which will be analyzed to better understand the role of these microorganisms. It's a chance to contribute to important research that could lead to new insights into this condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • • Diagnosis of Giant cell arteritis (only in one arm)
- Exclusion Criteria:
- • chronic infection (viral, fungi, bacteria) including human immunodeficiency viruses, Hepatitis B/C
- • acute infection with usage of antibiotics less then 90 days before screening
- • major gastro-intestinal surgery \<5 years from screening
- • gastro-intestinal bleeding \<90 days before screening
- • inflammatory bowel disease (confirmed bioptically)
- • bulimia or anorexia nervosa
- • adipositas (body mass index ≥ 40)
- • intake of high dosage of probiotics (\>10\^9 colony forming units per day) \<90 days before screening
- • not controlled Diabetes mellitus
- • Malignancy within one year (except for squamous skin - and basal skin carcinoma without metastasis, cervix carcinoma with curative surgery, Cutaneous T-cell lymphoma)
- • known abuse of alcohol oder drugs.
About University Of Bonn
The University of Bonn is a renowned academic institution dedicated to advancing medical research and education. With a strong emphasis on interdisciplinary collaboration, the university engages in cutting-edge clinical trials aimed at improving patient outcomes and advancing healthcare knowledge. Its comprehensive research programs are supported by state-of-the-art facilities and a commitment to ethical standards in clinical practice. By fostering partnerships with healthcare professionals and industry leaders, the University of Bonn plays a pivotal role in translating scientific discoveries into innovative therapeutic solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bonn, , Germany
Bonn, North Rhine Westphalia, Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported